3 British Healthcare Stocks With Earnings Growth Over 14%

Stronger UK GDP data, with 0.7% growth in the third quarter, has put the spotlight back on sectors tied to long term spending like healthcare. If the Bank of England tightens policy from here, balance sheet strength and resilient demand can matter more than fashion. This article walks through three leading British healthcare stocks from our screener that combine financial robustness with long term industry tailwinds.

The three healthcare stocks that follow are just a first pass from the wider screen. The full set of results includes 3 more businesses with equally compelling stories that are not covered below.

If you want to go beyond the short list and really pressure test ideas, head straight into the Best Healthcare Stocks screener to identify, filter and analyze the highest conviction healthcare opportunities.

NIOX Group (AIM:NIOX)

NIOX Group focuses on respiratory diagnostics in healthcare, designing and selling its NIOX VERO point of care device and consumables that measure FeNO to help manage asthma and COPD. The business currently generates about £48 million from NIOX branded products and has a market value near £268 million.

NIOX Group provides focused exposure to respiratory testing equipment, with FeNO-based NIOX VERO used directly in clinics and hospitals. The combination of specialist hardware, recurring consumables and a relatively high valuation means margins and growth are closely linked to changes in adoption momentum in asthma and COPD testing.

If you want to see whether that premium on NIOX Group is justified by the underlying fundamentals, start with the DCF valuation analysis for NIOX Group for a clear reality check.

HUTCHMED (China) (AIM:HCM)

HUTCHMED (China) develops oncology and immunology drugs that fit squarely within the Best Healthcare Stocks theme, with oncology and immunology contributing about US$304 million of its roughly US$549 million in segment revenue alongside US$245 million from other ventures, and the stock valued at about £1.95 billion.

HUTCHMED (China) gives the screener serious late stage cancer exposure, and the bearish analyst Narrative on Simply Wall St captures why the oncology pipeline, partner deals and spending plans all matter so much to the long term appeal of this stock.

"Although HUTCHMED is pointing to ATTC assets like A251 and A580 enrolling well and targeting around five programs in the clinic by mid 2027, any safety issues, slower recruitment, or weaker than expected 2027 readouts could force longer development timelines and higher R&D spending, which would weigh on earnings and test the commitment to remain breakeven."

The real swing factor is how one pressure on future oncology cash flows ultimately filters through to pricing power, margins and investor patience.

That pressure on sentiment is exactly why reading the full narrative for HUTCHMED (China) can help you see where oncology momentum, partnerships and cash needs might be quietly decoupling from headline worries.

AstraZeneca (LSE:AZN)

AstraZeneca is a global biopharmaceutical group focused on prescription medicines across oncology, cardiometabolic disease, respiratory and immunology, vaccines and rare conditions. It generates about US$62.4b from pharmaceuticals and carries a market value near £215.5b.

AstraZeneca fits the Best Healthcare Stocks theme through a broad portfolio of prescription drugs anchored in oncology and cardiometabolic care. The analyst consensus Narrative on Simply Wall St highlights how that breadth now connects to a very specific late stage opportunity set.

"The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular or metabolic therapies, is now underpinned by management's disclosure of 12 programs each with risk adjusted peak sales potential above US$5b and several more in the US$3b to US$5b range."

What ultimately happens to earnings and valuation depends heavily on how one unseen pressure in that late stage portfolio resolves over the next few years.

That hidden pressure point makes context crucial, so read the full narrative for AstraZeneca to see how AstraZeneca's late stage engine could still surprise on earnings power.

Seeking Fresh Alternatives Beyond Healthcare?

Fresh ideas move first. Markets often reward investors who identify momentum before it turns into headlines and while it still has an impact. Do not get caught watching. Consider your options in a timely way.

• Look for powerful cash engines early by scanning 17 high quality undervalued stocks, focusing on companies that balance solid balance sheets with pricing that appears misaligned with underlying business quality.
• Follow potential infrastructure opportunities by tracking 42 power grid technology and infrastructure stocks to monitor developments related to grid upgrades, electrification spending and hardware demand as they evolve in investor expectations.
• Monitor robotics opportunities by reviewing 87 robotics and automation stocks, which highlights automation businesses involved in workflows that are moving from manual processes toward machine-based solutions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com